2024
Menopausal hormone therapy: assessing associations with breast and colorectal cancers by familial risk
Macinnis R, Jenkins M, Milne R, John E, Daly M, Andrulis I, Colonna S, Phillips K, Investigators K, Le Marchand L, Newcomb P, Phipps A, Schmit S, Macrae F, Buchanan D, Gallinger S, Pai R, Samadder N, Giles G, Southey M, Hopper J, Terry M. Menopausal hormone therapy: assessing associations with breast and colorectal cancers by familial risk. JNCI Cancer Spectrum 2024, pkae121. PMID: 39673461, DOI: 10.1093/jncics/pkae121.Peer-Reviewed Original ResearchFamily risk scoreMenopausal hormone therapyFamilial riskHazard ratioColorectal cancerFamilial risk of BCBreast cancerFamily historyDecreased colorectal cancerCancer family historyRisk of BCIncreased breast cancerAssociated with breastIncident BCNever usersGeneral populationRisk scoreHarmonized dataWomenHormone therapyRiskAssociationCancerNeverCohort
2023
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024.
Daly M, Pal T, Maxwell K, Churpek J, Kohlmann W, AlHilli Z, Arun B, Buys S, Cheng H, Domchek S, Friedman S, Giri V, Goggins M, Hagemann A, Hendrix A, Hutton M, Karlan B, Kassem N, Khan S, Khoury K, Kurian A, Laronga C, Mak J, Mansour J, McDonnell K, Menendez C, Merajver S, Norquist B, Offit K, Rash D, Reiser G, Senter-Jamieson L, Shannon K, Visvanathan K, Welborn J, Wick M, Wood M, Yurgelun M, Dwyer M, Darlow S. NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024. Journal Of The National Comprehensive Cancer Network 2023, 21: 1000-1010. PMID: 37856201, DOI: 10.6004/jnccn.2023.0051.Peer-Reviewed Original ResearchConceptsGenetic/Familial High-Risk AssessmentNCCN guidelinesHigh-risk assessmentProstate cancerLP variantsGenetic counseling/testingNCCN Guidelines InsightsRisk of breastLi-Fraumeni syndromeUterine cancerOvarian cancerBreast cancerHereditary predispositionCare strategiesRisk reduction strategiesPathogenic variantsCancerBreastOvarianGender diverse peopleImportant updatesGuidelinesAssessmentSyndromePancreatic
2020
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.
Daly M, Pilarski R, Yurgelun M, Berry M, Buys S, Dickson P, Domchek S, Elkhanany A, Friedman S, Garber J, Goggins M, Hutton M, Khan S, Klein C, Kohlmann W, Kurian A, Laronga C, Litton J, Mak J, Menendez C, Merajver S, Norquist B, Offit K, Pal T, Pederson H, Reiser G, Shannon K, Visvanathan K, Weitzel J, Wick M, Wisinski K, Dwyer M, Darlow S. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. Journal Of The National Comprehensive Cancer Network 2020, 18: 380-391. PMID: 32259785, DOI: 10.6004/jnccn.2020.0017.Peer-Reviewed Original ResearchConceptsGenetic/Familial High-Risk AssessmentHigh-risk assessmentGenetic testingNCCN Guidelines InsightsHereditary cancer syndromesHigh-penetrance genesNCCN panelNCCN guidelinesSystemic therapyAshkenazi Jewish ancestryMost recent recommendationsRelevant new dataPancreatic cancerOvarian cancerCancer syndromesRecent recommendationsCancerBreastSyndromeOvarianManagement recommendationsJewish ancestryRisk management recommendations
2018
Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.
Bevers TB, Helvie M, Bonaccio E, Calhoun KE, Daly MB, Farrar WB, Garber JE, Gray R, Greenberg CC, Greenup R, Hansen NM, Harris RE, Heerdt AS, Helsten T, Hodgkiss L, Hoyt TL, Huff JG, Jacobs L, Lehman CD, Monsees B, Niell BL, Parker CC, Pearlman M, Philpotts L, Shepardson LB, Smith ML, Stein M, Tumyan L, Williams C, Bergman MA, Kumar R. Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2018, 16: 1362-1389. PMID: 30442736, DOI: 10.6004/jnccn.2018.0083.Peer-Reviewed Original ResearchConceptsBreast cancer screeningCancer screeningNCCN Clinical Practice GuidelinesBreast cancer screening recommendationsCancer screening recommendationsClinical practice guidelinesAbnormal imagingNCCN guidelinesScreening recommendationsPhysical findingsBreast cancerDiagnostic evaluationFull guidelinePractice guidelinesClinical decisionDiagnosisGuidelinesScreeningCancerOncology
2015
Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation
Gronwald J, Glass K, Rosen B, Karlan B, Tung N, Neuhausen S, Moller P, Ainsworth P, Sun P, Narod S, Lubinski J, Kotsopoulos J, Group B, Lynch H, Cybulski C, Kim-Sing C, Friedman S, Senter L, Weitzel J, Singer C, Eng C, Mitchell G, Huzarski T, McCuaig J, Eisen A, Gilchrist D, Blum J, Zakalik D, Pal T, Daly M, Weber B, Snyder C, Fallen T, Chudley A, Lunn J, Donenberg T, Kurz R, Saal H, Garber J, Rennert G, Sweet K, Rappaport C, Lemire E, Stoppa-Lyonnet D, Olopade O, Merajver S, Bordeleau L, Cullinane C, Friedman E, McKinnon W, Wood M, Rayson D, Meschino W, Costalas J, Reilly R, Vadaparampil S, Offit K, Kauff N, Euhus D, Kwong A, Isaacs C, Couch F, Manoukian S, Byrski T, Elser C, Panchal S, Armel S, Demsky R, Nanda S, Metcalfe K, Poll A, Foulkes W, Robidoux A, Warner E, Maehle L, Evans G, Pasini B, Ginsburg O, Cohen S, Jakubowska A, Little J. Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Fertility And Sterility 2015, 105: 781-785. PMID: 26698676, DOI: 10.1016/j.fertnstert.2015.11.034.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBRCA1 ProteinBRCA2 ProteinCase-Control StudiesChi-Square DistributionDNA Mutational AnalysisFemaleFertilityFertility Agents, FemaleFertilization in VitroGenetic Predisposition to DiseaseHumansInfertilityInsemination, ArtificialLogistic ModelsMiddle AgedMultivariate AnalysisMutationOdds RatioOvarian NeoplasmsPregnancyReproductive Techniques, AssistedRisk AssessmentRisk FactorsSurveys and QuestionnairesTreatment OutcomeYoung AdultConceptsRisk of ovarian cancerOvarian cancerTreatment of infertilityBRCA2 mutationsEstimate odds ratiosBRCA2 mutation carriersConditional logistic regressionFertility medicationsDiagnosis of ovarian cancerCase-control studyOdds ratioBRCA mutationsMutation carriersLogistic regressionAdministered questionnairesIVF treatmentBRCA2BRCA1CancerInfertilityInfertility treatmentWomenRiskMedicationTreatmentBreast Cancer Risk Reduction, Version 2.2015.
Bevers T, Ward J, Arun B, Colditz G, Cowan K, Daly M, Garber J, Gemignani M, Gradishar W, Jordan J, Korde L, Kounalakis N, Krontiras H, Kumar S, Kurian A, Laronga C, Layman R, Loftus L, Mahoney M, Merajver S, Meszoely I, Mortimer J, Newman L, Pritchard E, Pruthi S, Seewaldt V, Specht M, Visvanathan K, Wallace A, Bergman M, Kumar R. Breast Cancer Risk Reduction, Version 2.2015. Journal Of The National Comprehensive Cancer Network 2015, 13: 880-915. PMID: 26150582, DOI: 10.6004/jnccn.2015.0105.Peer-Reviewed Original Research
2014
Genetic/familial high-risk assessment: breast and ovarian, version 1.2014.
Daly M, Pilarski R, Axilbund J, Buys S, Crawford B, Friedman S, Garber J, Horton C, Kaklamani V, Klein C, Kohlmann W, Kurian A, Litton J, Madlensky L, Marcom P, Merajver S, Offit K, Pal T, Pasche B, Reiser G, Shannon K, Swisher E, Voian N, Weitzel J, Whelan A, Wiesner G, Dwyer M, Kumar R. Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. Journal Of The National Comprehensive Cancer Network 2014, 12: 1326-38. PMID: 25190698, DOI: 10.6004/jnccn.2014.0127.Peer-Reviewed Original ResearchConceptsNCCN GuidelinesAssessment of genetic mutationsGenetic/Familial High-Risk AssessmentDevelopment of breastManagement of patientsHamartoma tumor syndromeOvarian cancerGenetic aberrationsGenetic testing/counselingTumor syndromeIncreased riskGenetic mutationsHigh-risk assessmentDiagnostic criteriaBreastNCCNMutationsBRCA1/BRCA2Genetic/FamilialTP53PatientsSyndromeCancerCowdenGuidelinesAssessment of Interest for Breast Cancer Prevention Trial Participation among BRCA Mutation Carriers
Rachel M, Vera S, Mary D, Sumithra M, Paul J, S, Pruthi. Assessment of Interest for Breast Cancer Prevention Trial Participation among BRCA Mutation Carriers. Hereditary Genetics 2014, 03 DOI: 10.4172/2161-1041.1000127.Peer-Reviewed Original Research
2013
Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer
Purrington K, Slager S, Eccles D, Yannoukakos D, Fasching P, Miron P, Carpenter J, Chang-Claude J, Martin N, Montgomery G, Kristensen V, Anton-Culver H, Goodfellow P, Tapper W, Rafiq S, Gerty S, Durcan L, Konstantopoulou I, Fostira F, Vratimos A, Apostolou P, Konstanta I, Kotoula V, Lakis S, Dimopoulos M, Skarlos D, Pectasides D, Fountzilas G, Beckmann M, Hein A, Ruebner M, Ekici A, Hartmann A, Schulz-Wendtland R, Renner S, Janni W, Rack B, Scholz C, Neugebauer J, Andergassen U, Lux M, Haeberle L, Clarke C, Pathmanathan N, Rudolph A, Flesch-Janys D, Nickels S, Olson J, Ingle J, Olswold C, Slettedahl S, Eckel-Passow J, Anderson S, Visscher D, Cafourek V, Sicotte H, Prodduturi N, Weiderpass E, Bernstein L, Ziogas A, Ivanovich J, Giles G, Baglietto L, Southey M, Kosma V, Fischer H, Network T, Reed M, Cross S, Deming-Halverson S, Shrubsole M, Cai Q, Shu X, Daly M, Weaver J, Ross E, Klemp J, Sharma P, Torres D, Rüdiger T, Wölfing H, Ulmer H, Försti A, Khoury T, Kumar S, Pilarski R, Shapiro C, Greco D, Heikkilä P, Aittomäki K, Blomqvist C, Irwanto A, Liu J, Pankratz V, Wang X, Severi G, Mannermaa A, Easton D, Hall P, Brauch H, Cox A, Zheng W, Godwin A, Hamann U, Ambrosone C, Toland A, Nevanlinna H, Vachon C, Couch F. Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis 2013, 35: 1012-1019. PMID: 24325915, PMCID: PMC4004200, DOI: 10.1093/carcin/bgt404.Peer-Reviewed Original ResearchConceptsTN breast cancerTriple-negative breast cancerBreast cancerBreast cancer susceptibility lociRisk factorsPolygenic risk scoresSingle nucleotide polymorphismsGenome-wide association studiesBreast cancer riskCancer susceptibility lociBreast cancer risk predictionGenetic risk factorsCancer risk predictionAbsolute riskAggressive subtypeAssociation studiesTwo-stage genome-wide association studyCancer riskRisk scoreSusceptibility lociGenome-wide significant associationSignificant associationCancerBreast cancer risk variantsPTHLH locus
2012
Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
Bolton K, Trench G, Goh C, Sadetzki S, Ramus S, Karlan B, Lambrechts D, Despierre E, Barrowdale D, McGuffog L, Healey S, Easton D, Sinilnikova O, Benítez J, García M, Neuhausen S, Gail M, Hartge P, Peock S, Frost D, Evans D, Eeles R, Godwin A, Daly M, Kwong A, K. E, Lázaro C, Blanco I, Montagna M, D'Andrea E, Nicoletto M, Johnatty S, Kjær S, Jensen A, Høgdall E, Goode E, Fridley B, Loud J, Greene M, L. P, Chetrit A, Lubin F, Hirsh-Yechezkel G, Glendon G, Andrulis I, Toland A, Senter L, Gore M, Gourley C, Michie C, Song H, Tyrer J, Whittemore A, McGuire V, Sieh W, Kristoffersson U, Olsson H, Borg Å, Levine D, Steele L, Beattie M, Chan S, Nussbaum R, Moysich K, Gross J, Cass I, Walsh C, Li A, Leuchter R, Gordon O, Garcia-Closas M, Gayther S, Chanock S, Antoniou A, Pharoah P, Investigators A. Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer. JAMA 2012, 307: 382-389. PMID: 22274685, PMCID: PMC3727895, DOI: 10.1001/jama.2012.20.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerInvasive epithelial ovarian cancerBRCA2 carriersOvarian cancerGermline mutationsOverall survivalInvasive EOCEpithelial ovarian cancer casesEffect of BRCA1BRCA2 mutation carriersSurvival of womenYear of diagnosisPathogenic germline mutationsBRCA1 carriersBRCA2 mutationsBRCA carriersFavorable survivalImprove prognosisSurvival differencesMutation carriersBRCA2Pooled analysisBRCA1Observational studyCancer
2011
Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes
Rebbeck T, Mitra N, Domchek S, Wan F, Friebel T, Tran T, Singer C, Tea M, Blum J, Tung N, Olopade O, Weitzel J, Lynch H, Snyder C, Garber J, Antoniou A, Peock S, Evans D, Paterson J, Kennedy M, Donaldson A, Dorkins H, Easton D, Rubinstein W, Daly M, Isaacs C, Nevanlinna H, Couch F, Andrulis I, Freidman E, Laitman Y, Ganz P, Tomlinson G, Neuhausen S, Narod S, Phelan C, Greenberg R, Nathanson K. Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Research 2011, 71: 5792-5805. PMID: 21799032, PMCID: PMC3170727, DOI: 10.1158/0008-5472.can-11-0773.Peer-Reviewed Original ResearchConceptsOvarian cancer riskCancer riskAssociation of haplotypesAssociated with ovarian cancer riskBreast cancerBRCA1 mutationsModifiers of cancer riskFalse discovery rateEncode proteinsBRCA1-associated breast cancerElevated cancer riskBRCA1 mutation carriersInherited BRCA1 mutationsOvarian cancer diagnosisSignificant false discovery rateAssociated with timeCancer diagnosisMutation carriersGenomic variationMultiple lociBRCA1BRCC45BreastCancerGenes
2004
Classifying Hereditary Cancers and Phenocopies of Hereditary Cancers Using Expression Arrays
Daly M, Parlanti A, Duggan D. Classifying Hereditary Cancers and Phenocopies of Hereditary Cancers Using Expression Arrays. 2004, 101-116. DOI: 10.1002/047147665x.ch6.Peer-Reviewed Original Research
1998
Epidemiology and risk assessment for ovarian cancer.
Daly M, Obrams G. Epidemiology and risk assessment for ovarian cancer. Seminars In Oncology 1998, 25: 255-64. PMID: 9633839.Peer-Reviewed Original ResearchConceptsIncidence of ovarian cancerOral contraceptive useOvarian cancerAssociated with increased ovarian cancer riskIncidence rate of ovarian cancerContraceptive useRisk of ovarian cancerRate of ovarian cancerOvarian cancer riskAsian American womenNative American womenPregnancy historyHawaiian womenFamily historyCancer riskWoman's riskRisk factorsIncidence rateAmerican womenCancerAfrican AmericansWomenCosmetic talcIncidenceUnited States
1996
Breast cancer and mammography: an American Cancer Society profile of Philadelphia and Montgomery Counties.
Norman S, Daly M, McCorkle R, Rogers J, Weinberg G, Finnegan E. Breast cancer and mammography: an American Cancer Society profile of Philadelphia and Montgomery Counties. Cancer Practice 1996, 4: 68-75. PMID: 8715443.Peer-Reviewed Original ResearchConceptsMammography providersAmerican Cancer Society goalsBreast cancer screening practicesIncidence of breast cancerCancer screening practicesBreast cancerPhiladelphia DivisionAmerican Cancer SocietyScreening practicesCancer SocietyBreast cancer detectionMammographyOutreach programsProgrammatic initiativesMontgomery CountyProvidersBreastCancer detectionAmericanCountyCancerSociety's goalsSurveyMammogramsPhiladelphia
1993
Ovarian cancer risk counseling: a guide for the practitioner.
Daly M, Lerman C. Ovarian cancer risk counseling: a guide for the practitioner. Oncology 1993, 7: 27-34; discussion 34, 37-8, 41. PMID: 8280574.Peer-Reviewed Original ResearchConceptsLong-term disease-free survivalStage III or IV diseaseDisease-free survivalEpithelial ovarian cancerEarly stage diseaseNon-specific symptomsIV diseaseImmunologic compromiseOvarian cancerStage diseaseGynecologic cancerChemotherapeutic approachesDiagnosed casesNatural historyPainful deathDiseaseCancerDeathUnited StatesPainPatientsMalnutritionYearsSurvivalSymptoms
1985
Breast Cancer Prognosis in a Mixed Caucasian-Hispanic Population23
Daly M, Clark G, McGuire W. Breast Cancer Prognosis in a Mixed Caucasian-Hispanic Population23. Journal Of The National Cancer Institute 1985, 74: 753-757. PMID: 3857371, DOI: 10.1093/jnci/74.4.753.Peer-Reviewed Original ResearchConceptsHispanic womenYears of ageCaucasian womenIncidence of breast cancerPopulation of Hispanic womenProportion of Hispanic womenER statusLymph nodesEstrogen receptorBreast cancerPositive axillary lymph nodesPositive lymph nodesAxillary lymph nodesExtent of diseaseBreast cancer prognosisPrognostic factorsComplete dataAge groupsMultivariate analysisCancer prognosisWomenBreastCancerAgeStatus